Summary
A UK observational study followed 8,127 women receiving GLP-1-based treatment through a structured digital care programme. Among those with six-month weight measurements, average weight loss was 15.5% of starting weight.
A six-month observational study of 8,127 women in the UK found that participants receiving GLP-1-based treatment through a structured digital care programme lost an average of 15.5% of their starting weight among those with follow-up measurements. The study, published in Nature Medicine, also recorded changes in blood-sugar and lipid measures. Nearly all participants were prescribed tirzepatide.
The programme combined remote screening and home blood tests with clinician review, video-supported follow-up and dose adjustments based on participants’ progress and tolerability. The research describes outcomes in this particular service; it was not a comparison of digital care with in-person treatment.
A remote pathway with clinical oversight
The study analysed routinely collected data from adult women (female sex at birth) who entered the programme between 27 November 2024 and 31 January 2025. Participants paid a fixed fee for treatment, laboratory testing and digital support. Of the 8,127 women prescribed and sent treatment, 99.8% received tirzepatide, according to the study abstract.
Before treatment, participants completed online eligibility screening, identity checks and a home capillary blood test. The programme included weekly video-supported follow-up and weight reporting, monthly clinician review, and questionnaires required for medication refills. Clinicians could adjust or defer dose increases in response to weight change and side effects, rather than automatically escalating treatment. A symptom-management package was also provided.
At six months, the mean prescribed tirzepatide dose was 9.5 mg weekly. The study assessed weight change as its primary outcome, alongside blood markers, treatment continuation and reported side effects.
Weight and blood-marker changes
Among the 7,297 participants with six-month weight measurements, mean weight fell from 104.6 kg to 88.6 kg. The average reduction was 16.1 kg, or 15.5% of baseline weight. Overall, 83.1% of this group lost at least 10% of their starting weight, and 22.4% lost at least 20%.
Among the 6,245 participants with paired HbA1c measurements, average HbA1c fell by 3.3 mmol/mol over six months. HbA1c is a measure of average blood glucose over time. It returned below the study’s diabetes-range threshold in 131 of 155 participants who started in that range, and below its prediabetes threshold in 546 of 567 who started with prediabetes.
Among participants with paired lipid measurements, total cholesterol, LDL cholesterol and triglycerides also declined on average. HDL cholesterol fell modestly. These measurements describe changes during treatment; the study design cannot separate the contribution of the medicine from other influences on participants’ health and behaviour.
At six months, 91.4% of the full treatment group remained on therapy. At least one side effect was reported by 62.7%; among those reporting side effects, most described their worst symptom as mild or moderate. The study identified no serious treatment-related adverse events during follow-up.
Reading the results in context
The study provides prospective real-world implementation evidence for a remote programme that paired medication with regular monitoring and clinician-guided dose decisions. Its size and focus on women address a group that has been less represented in some obesity-treatment research. The results were broadly consistent across age, starting weight and socioeconomic groups, although 88.0% of participants were white.
The findings are observational, without a comparison group, and the programme was self-pay. The reported changes therefore describe outcomes among people using this service, rather than a controlled estimate of the effect of the medicine or the digital model. Follow-up covered six months, and the results may not represent people with different access to care or more complex health needs. Longer follow-up would be needed to assess how weight and treatment continuation change over time.